Innate Pharma S.A. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| OPTIVER HOLDING B.V. | 11/14/2024 | 86,788 | $198,745 | -0.65% | 0.11% |
| EXCHANGE TRADED CONCEPTS, LLC | 10/10/2024 | 77,350 | $177,132 | -10.31% | 0.10% |
| MORGAN STANLEY | 11/14/2024 | 43,524 | $99,670 | 0.00% | 0.05% |
| CITADEL ADVISORS LLC | 11/14/2024 | 21,267 | $48,701 | -9.61% | 0.03% |
| UBS GROUP AG | 11/14/2024 | 8,408 | $19,254 | 2,730.98% | 0.01% |
| BARCLAYS PLC | 11/19/2024 | 307 | $1,000 | -25.49% | 0.00% |
| RHUMBLINE ADVISERS | 11/12/2024 | 205 | $469 | 0.00% | 0.00% |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 11/14/2024 | 200 | $458 | 0.00% | 0.00% |
Innate Pharma S.A.institutional Ownership - FAQ's
During the previous two years, 9 institutional investors and hedge funds held shares of Innate Pharma S.A.. The most heavily invested institutionals were:
Optiver Holding B.V.: 86,788
EXCHANGE TRADED CONCEPTS, LLC: 77,350
MORGAN STANLEY: 43,524
CITADEL ADVISORS LLC: 21,267
UBS Group AG: 8,408
BARCLAYS PLC: 307
0.30% of Innate Pharma S.A. stock is owned by institutional investors.
Institutional investors have bought a total of 238,064 shares in the last 24 months. This purchase volume represents approximately $502,315 in transactions.